BioNTech Success Depends On Cancer Therapy Pipeline
BioNTech's long-term profitability depends on the effectiveness of its current cancer therapy research pipeline. The company maintains cash reserves, allowing for continued high spending on research and development.
Topics
Developing
- 862d Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore.
- 862d Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
- 862d Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est.
- 862d Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium.
Sources · 7 independent
hr-iNFO
“Das hängt aus meiner Sicht jetzt wirklich vollständig von der Pipeline ab, die da im Bereich Krebstherapie. Die Krebsmedikamente müssen langfristig funktionieren, damit das Unternehmen irgendwann auch wieder schwarze Zahlen schreiben kann.”
Unlock the full story
Get a Pro subscription or above to see the live story progression and the full list of independent sources confirming each event as they happen.
Log in to upgrade